Ivabradine Cristers

Ivabradine, the active ingredient in Ivabradine Cristers, is a If channel inhibitor presented as an oral formulation for oral use. It lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradine Cristers as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to control heart rate, making it useful in specific cardiovascular conditions.

- Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction: improves symptoms and may decrease hospitalisations related to heart failure.

Ivabradine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: slower than normal heart rate. - Headache: mild to moderate intensity. - Dizziness: sensation of light‑headedness. - Fatigue: reduced energy levels.

Serious or Rare Side Effects: - Severe bradycardia requiring medical attention. - Atrial fibrillation or other significant arrhythmias. - Symptomatic hypotension. - Persistent visual loss. - Myocardial ischaemia exacerbation.

Before initiating therapy, clinicians should consider several safety aspects.

- Baseline heart‑rate assessment: ensure resting rate is above the recommended threshold. - Concomitant bradycardic agents: monitor for excessive slowing when used with beta‑blockers or digoxin. - CYP3A4 inhibitors: avoid strong inhibitors or adjust therapy as needed. - Pregnancy and lactation: safety data are limited; use only if benefits outweigh risks. - Renal or hepatic impairment: evaluate function and consider dose modification. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ivabradine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase plasma levels. - Other heart‑rate‑lowering drugs (beta‑blockers, digoxin): risk of profound bradycardia. - Drugs that cause QT prolongation: additive risk of arrhythmias.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Nitrates or other anti‑anginal agents: monitor for overlapping cardiovascular effects.